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Abstract
Autism and schizophrenia are neurodevelopmental disorders which both have highly disabling negative and
cognitive symptoms with few effective treatments. A challenge to developing effective therapeutics is a dearth
of pre-clinical models. Part of the difficulty in developing predictive models is that the symptoms being
treated are complex, and difficult to reduce to a simple behavioral task. Therefore, the use of endophenotypes
from methods such as EEG presents a new promising avenue for a model of complex human behaviors pre-
clinically. New evidence suggests that autism and schizophrenia have reliable electrophysiological
endophenotypes, some of which have been correlated to negative and cognitive symptoms. These
endophenotypes therefore represent a possible new pathway for understanding the disrupted circuits in both
diseases and developing treatments.
Evidence has been accumulating for glutamate disruption in both schizophrenia and autism; accordingly, pre-
clinical models are being developed around NMDA receptor (NMDAR) disruption to examine both diseases.
NMDA disruption models have been used for many behavioral tasks, but only a few possible
electrophysiological endophenotypes such as ERP amplitudes have been investigated. Investigating pre-
clinical models of established clinical endophenotypes could lead to better translational biomarkers of disease
symptoms.
This thesis's unifying theme is the study of how glutamate disruption can recreate the electrophysiological
endophenotypes present in autism and schizophrenia and develop their use as translational biomarkers in
both diseases. The primary models of focus are acute NMDA antagonist administration and NMDAR
knockdown of PV interneurons. I used these models to examine the relationship between dose and EEG
changes, along with the perturbations present with NMDAR disruption in PV interneurons. I investigated the
degree to which NMDAR antagonists recreate signal-to-noise ratio (SNR) and timing perturbations in
schizophrenia, and found a dose-dependent decrease in SNR and timing consistency. I assessed the extent to
which low dose NMDAR antagonism recreates latency and gamma synchrony perturbations present in autism
and found latency was increased and gamma synchrony was decreased dose-dependently. I examined the
extent to which Parvalbumin (PV) containing interneurons cell type selective NR1 KO mice recreate the
clinical EEG profiles of autism and found selective deficits in social behavior and increases in N1 latency.
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Abstract 
NMDA RECEPTOR DYSFUNCTION AND DEVELOPMENT OF TRANSLATIONAL 
BIOMARKERS FOR AUTISM AND SCHIZOPHRENIA 
John A. Saunders IV 
Supervisor: Steven J. Siegel 
Autism and schizophrenia are neurodevelopmental disorders which both have 
highly disabling negative and cognitive symptoms with few effective treatments. A 
challenge to developing effective therapeutics is a dearth of pre-clinical models. Part of 
the difficulty in developing predictive models is that the symptoms being treated are 
complex, and difficult to reduce to a simple behavioral task. Therefore, the use of 
endophenotypes from methods such as EEG presents a new promising avenue for a 
model of complex human behaviors pre-clinically. New evidence suggests that autism 
and schizophrenia have reliable electrophysiological endophenotypes, some of which 
have been correlated to negative and cognitive symptoms (Light, Hsu et al. 2006; Dias, 
Butler et al. 2011). These endophenotypes therefore represent a possible new pathway for 
understanding the disrupted circuits in both diseases and developing treatments. 
One set of pre-clinical models for schizophrenia that have been studied 
extensively revolve around glutamate disruption. This is achieved by a variety of 
measures, including administration of NMDA antagonists, lesion, and genetic knockout 
(KO) of NMDA receptors (Dias, Butler et al. 2011; Fitzgerald 2012). More recently, 
evidence has been discovered that glutamate disruption may underlie some of the 
disruptions present in autism. Glutamate disruption models have been used for many 
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behavioral tasks, but they are often unable to elucidate the underlying circuit disruption. 
Furthermore, only a few possible endophenotypes such as ERP amplitudes have been 
investigated. Investigation into pre-clinical models of established clinical 
endophenotypes could lead to better translational biomarkers of disease symptoms, and 
speed therapeutic development. 
The unifying theme of the work that comprises this thesis is the study of how 
glutamate disruption can be used to recreate the electrophysiological endophenotypes 
present in autism and schizophrenia and develop their use as translational biomarkers in 
both diseases. The primary models of focus are acute NMDA antagonist administration 
and NMDA receptor knockdown of PV interneurons. Using these models, I examined the 
relationship between the dose and EEG changes, along with the perturbations present 
with NMDA disruption in PV interneurons. I investigated the degree to which NMDAR 
antagonists recreate signal-to-noise ratio (SNR) and timing perturbations in 
schizophrenia, and found a dose-dependent decrease in SNR and timing consistency. I 
assessed the extent to which low dose NMDAR antagonism recreates latency and gamma 
synchrony perturbations present in autism and found latency was increased and gamma 
synchrony was decreased in a dose-dependently. I examined the extent to which 
parvalbumin (PV) containing interneurons cell type selective NR1 KO mice recreate the 
clinical EEG profiles of autism and found selective deficits in social behavior and 
increases in N1 latency. 
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Chapter 1.1: General Introduction 
Schizophrenia and autism are disabling illnesses which occur in 2-4% of the 
population. They both result in a wide variety of negative symptoms, including 
anhedonia, avolition, deficits in social communication, and comprehension of emotion. In 
addition, there are often cognitive deficits which include reduced working memory and 
executive control. There are few effective treatments for the negative and cognitive 
symptoms present in both diseases. In both diseases, there is increasing evidence that N-
Methyl-D-aspartate (NMDA) receptor dysfunction is part of the driving mechanism for 
the untreated symptoms (Timofeeva and Levin 2011). In addition, robust 
electrophysiological biomarkers for both diseases have been discovered (Light, Hsu et al. 
2006; Roberts, Khan et al. 2010). 
In schizophrenia, there was initially interest in the dopamine system as dopamine 
antagonists were able to ameliorate the psychotic symptoms present in schizophrenia. 
Subsequent anti-psychotics were all based on a similar mechanism, though efficacy is 
unrelated to degree of dopamine antagonism. Also while, the drugs were effective in 
treating psychosis, they have little to no effect on the negative or cognitive symptoms 
present in schizophrenia that have the largest impact on patient quality of life. The 
inability to hold a job, be an active community member, and socially engaged often lead 
to depression, and contribute to a great extent of the disease burden on society. A new 
pathway for disease treatment has been explored, based on the observation that the 
NMDA antagonists phencyclidine and ketamine reproduced schizophrenia like psychosis, 
disorganization, and reduced cognitive function (Javitt 2010). Thus in an effort to attack 
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the as of yet untreatable symptoms, there has been extensive research into the glutamate 
system for ways to ameliorate the illness’s effects. 
Autism has recently come to the forefront with increased recognition of its 
existence by the general public and clinicians. While it does not possess the psychosis 
present in schizophrenia, it overlaps in the impaired social function with language deficits 
along with reduced ability to understand and interpret emotional content. Common 
comorbidities include cognitive deficits such as reduced working memory and executive 
function, along with anxiety that overlap with schizophrenia. In addition, there has been 
recent evidence that glutamate disruption on PV interneurons may be related to the 
deficits present in autism.  
In both diseases treatment has been attempted using traditional anti-psychotics 
with little success. While anti-psychotics such as risperidone are approved for use in both 
diseases, it only serves to control behavior such as angry outbursts. For other 
comorbidities such as anxiety and ADHD (more prevalent in autism), there are some 
treatments. Intensive behavioral therapy appears to help with some of the functional 
issues, but has had limited success in treating patients and fully restoring function. 
Overall, there is little that can be currently done to treat the core negative and cognitive 
symptoms these patients face. 
1.2 Animals as models of Human disease 
1.2.1 Criteria for pre-clinical models 
When investigating rodent models of autism and schizophrenia, it is important to 
establish the validity of the model before being extrapolating observed findings to the 
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clinical population (Crawley 2008; Chadman, Yang et al. 2009). “Construct validity” 
indicates that the preclinical model incorporates an analogous biological perturbation 
(e.g., genetic mutation, environmental insult) that is associated with the human disease. 
This stipulation is relatively straightforward, given the number of such insults that have 
been linked to autism spectrum disorders (ASDs) and schizophrenia (Betancur 2011; 
Greenwood, Lazzeroni et al. 2011). For genetic mutations, it is important that the 
orthologous genetic change is introduced into the mouse, instead of simply deleting the 
gene, because human disease-causing mutations can often be gain-of-function mutation 
(Tabuchi, Blundell et al. 2007). “Face validity” indicates that the preclinical model shows 
phenotypes (and endophenotypes) analogous to those seen in the human disorder. 
Importantly, this criterion should also incorporate specificity; that is, a valid animal 
model should not show neural abnormalities that are not observed in the clinical 
syndrome. Finally, “predictive validity” indicates that therapeutics which are effective in 
a preclinical setting translate successfully to the clinical population (and vice versa). 
Because antipsychotics like risperidone are the only FDA-approved drugs to treat some 
of autism’s symptoms and only psychosis in schizophrenia, but lack impact on negative 
symptoms in both diseases, this criterion is likely the least important. However, 
specificity is important here as well–a drug that has failed to improve negative symptoms 
in patients with autism or schizophrenia (e.g., anti-psychotics, SSRIs, or secretin) should 
not be effective in valid animal models (Williams, Wray et al. 2005; Williams, Wheeler 
et al. 2010). 
1.2.2 Assessing Model Specificity 
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When assessing the behavioral effects of genetic or environmental perturbations 
relevant to autism or schizophrenia in rodents, it is important to assess the specificity of 
such deficits. Autism is not caused by comprehensive neurological impairment, and the 
negative symptoms of schizophrenia can occur independent of psychosis. Global brain 
dysfunction in a mouse could manifest the negative symptoms present in both diseases. 
Therefore, it is important to rule out nonspecific cognitive and motor deficits. 
Comprehensive phenotypic characterization helps rule out potential behavioral confounds 
that could contribute to false positive results. For example, reduced social activity could 
be caused by deficits in olfactory function or reduced locomotor activity. In addition, 
discrete T-maze tests can test whether working and spatial memory is intact. Validation 
to test that our induced deficits are specific to certain set of symptoms as opposed to 
generalized neural impairment is instrumental to creating models effective in guiding 
therapeutic development. 
1.3 NMDAR disruption and Schizophrenia 
1.3.1 Clinical Evidence for Connection 
Initial evidence for glutamate disruption as the pathway for schizophrenia, was 
found from clinical reports that abusers of PCP or ketamine exhibited schizophrenia like 
symptoms. Research has also revealed that a compound’s ability to recreate 
schizophrenia like symptoms was related to its degree of NMDA receptor binding 
independent of other receptor types (Javitt and Zukin 1991). In addition, conditions such 
as anti-NMDA receptor encephalitis induce similar symptoms. Furthermore, there is 
evidence that NMDA receptors are disrupted in patients with schizophrenia (Javitt 2010). 
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A report from the Consortium on the Genetics of Schizophrenia showed evidence that 
multiple proteins involved in the NMDAR pathway are highly associated with features of 
schizophrenia, and that the NMDAR pathway was most represented in the genetic studies 
(Greenwood, Lazzeroni et al. 2011). 
1.3.2 Animal models 
1.3.2.1 NMDA Receptor Antagonist models 
Since the discovery by Javitt that abusers of NMDA antagonists ketamine and 
PCP exhibited schizophrenia like psychosis, and then subsequent clinical trials with the 
agent showed similar results NMDA antagonists have been hypothesized to be a 
schizophrenia model (Javitt 2010). In addition, acute administration in preclinical models 
recreates many schizophrenia symptoms including psychosis, working memory deficits, 
asociability, and reduced prepulse inhibition (PPI) of startle (van der Staay, Rutten et al. ; 
Javitt and Zukin 1991; Zou, Zhang et al. 2008). In addition, administration of NMDA 
antagonists reduces parvalbumin interneuron expression, in agreement with post-mortem 
findings in schizophrenia (Lewis, Curley et al. 2012). These developments have provided 
evidence that NMDA antagonist administration models may be useful for understanding 
and dissecting Schizophrenia. 
1.3.2.2 Genetic Models 
Genetic knockout models have been used to provide selectivity to NMDAR 
models, and incorporate the developmental aspects of reduced NMDAR function. Several 
models including neuregulin, constitutive 90% reduction of NMDA receptors, and cell 
type selective NMDAR knockdown of either interneurons or pyramidal cells have been 
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created to study the effects of NMDAR in a variety of scenarios. This allows for 
developmental evaluation of the effects of different receptor knockdowns. 
1.4 NMDAR disruption and Autism 
1.4.1 Clinical Evidence for Connection 
Many genes related to autism and it cognitive disabilities are on the NMDA 
pathway (Marco, Hinkley et al. 2011). Genes encoding NMDA receptor subunit proteins 
such as GRIN1 GRIN2A, GRIN2B, GRIN2C, and ERBB4 have been implicated autism 
and lie in the NMDA receptor pathway. There is also data to indicate NMDAR signaling 
is a key deficit in several mouse models of autism risk genes including UBE3A, NRXN1, 
MeCP2, DISC1, and SHANK.  
1.4.2 Animal models 
1.4.2.1 NMDA Receptor Antagonist models 
Low level administration of NMDAR antagonists induce social and cognitive 
deficits similar to those found in autism. In addition, low dose administration of the 
NMDA antagonist MK801 recreates the robust electrophysiological endophenotype of 
N1 latency delay. Furthermore, administration of NMDAR antagonists can cause the 
reduced evoked power and inter-trial coherence present in autism. 
1.4.2.2 Genetic Models 
Several models of autism risk genes have been used as mentioned above. Recent 
evidence indicates that selective disruption of NMDARs on PV interneurons causes N1 
7 
 
latency delays and selective deficits in social behavior, providing evidence for NMDAR 
interneuron disruption as a mechanism of autism deficits. 
1.5 Analysis methods 
1.5.1 ERP Methods 
Studies from the Siegel laboratory and others have shown a high degree of 
similarity between human and mouse EEG measures and auditory event-related potentials 
(ERPs) in terms of waveform morphology, as well as physiological and pharmacological 
response properties. These measures offer greater translatability than behavioral 
phenotypes as they can be investigated using the same auditory paradigms in preclinical 
and clinical studies, while giving responses with analogous components such as the 
P20/P50 and N40/N100 between mouse/human (Connolly, Maxwell et al. 2003; 
Umbricht, Vyssotky et al. 2004; Metzger, Maxwell et al. 2007). We have demonstrated 
that schizophrenia-like auditory-ERP deficits, such as reduced P1/N1 amplitude and 
habituation, can be recreated using pharmacological manipulations that disrupt 
neurotransmitter systems involved in schizophrenia pathophysiology, including 
dopamine, acetylcholine, and glutamate systems (Siegel, Maxwell et al. 2005; Maxwell, 
Ehrlichman et al. 2006; Phillips, Ehrlichman et al. 2007). Similar abnormalities have 
been demonstrated in transgenic mice with mutations in schizophrenia risk genes, 
including DTNBP1, NRG1, and GRIN1, which regulate glutamatergic signaling (Carlson, 
Talbot et al. ; Ehrlichman, Luminais et al. 2009; Halene, Ehrlichman et al. 2009). A 
graphical illustration of the wave and how components are measured are as follows: 
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Figure 1.5.1a- One epoch of an EEG stimulus response 
 
Figure 1.5.1b- Method for amplitude measurement 
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Figure 1.5.1c- Method for latency measurement 
1.5.2 Data Integrity Methods 
To protect data integrity, methods are implemented to reduce artifacts, and reject 
any that are recorded. As a first pass, the connectors to the mice are taped down to reduce 
motion artifacts, next the data is band pass filtered between 1 and 500 Hz to reduce DC 
electrical noise and high frequency aliasing. The data is then examined manually for 
ungrounding artifacts where the system steps between maximum voltages, see figures 
below.  
Before a mouse is run for data collection, a test run is performed to check for the 
following abnormalities in the raw signal (y-axis is signal in µV and x-axis is time in 
seconds). 
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Figure 1.5.2a - Too Saturated (bad 
reference/electrode surgery)  
Figure 1.5.2b- Too Regular (bad surgery)
 
Figure 1.5.2c- Too thick (poor grounding)  See line cycle noise on zoom 
 
If these patterns are observed in the pre-test run, the equipment is re-hooked. If this 
doesn’t fix the problem, then it is likely the mouse has a failed surgery and is sacrificed. 
Figure 1.5.2d- Good signals are as follows: 
  
11 
 
Next when the data is gated into EEGLab, a pass is made to reject trials that fall more 
than 2 standard deviations from the mean. After analysis of the various EEG measures, 
each data point is subject to outlier rejection if they fall more than two standard 
deviations over the mean. 
1.5.3 Wavelet Method advantages 
In Fourier analysis, there is always a tradeoff between time and frequency 
resolution. For any signal that is narrow in the time band or frequency band, it will be 
broadband in the other domain. In the extreme case, there is the Fourier Transform that 
has no time resolution but very fine frequency resolution. While this provides some 
useful information, many neural processes are transient, and there is interest in capturing 
the responses rather than all activity. One step in this direction is the use of a method 
called short time Fourier transform, where short windows of time are Fourier 
transformed, and used to track the brain’s response. While this is superior to the Fourier 
transform in capturing transient activity, it is unable to scale based on frequency. For 
example, if activity from 4 Hz Theta to 100 Hz High Gamma is of interest, there is a 
conflict, because a window of at least 250 ms (1 second/4 Hz) is required to calculate the 
time-frequency information for the theta range, but when the same window is applied at 
100 Hz, it unnecessarily sacrifices useful temporal information for little gain frequency 
information. Wavelets circumvent this problem by having higher frequency resolution 
and wider windows at low frequencies, and shorter time windows at higher resolutions. 
This allows the calculation technique to be optimized to the transient changes in each 
frequency domain. 
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1.5.4 Wavelet Method description 
Formula for power calculations:  (    )   (    )   ( )
  
Formula for ITC calculations:   (    )   (    )    ( )   (    )    ( )  which give the 
complex phases, the phases are then averaged. Phase locking factor, a measure of inter-
trial coherence, is then calculated by taking the modulus of the average phase. For a 
complex number z=x+yi, the modulus of z is    √     . 
The phase can be calculations can be visualized as the averaging of the phase unit vectors 
for each trial, then taking the modulus 
Figure 1.5.4a- One trial’s unit 
 phase vector:   
 
To improve analysis, a range of wavelet families with cycle numbers (
  
  
), varying 
linearly from 2 to 10 from the lowest frequency to the highest frequency were used. 
Sacrificing some frequency spread at low frequencies to improve temporal spread, while 
at high frequencies sacrifices temporal spread to improve frequency spread. 
Term definitions: 
  ( ) is the signal 
   ( ) is the signal for each trial 
  (    ) is the wavelet equation equal to    
      
 ⁄           
 A is the normalization constant (    )
   ⁄  so total energy is equal to 1 
    is the time standard deviation, two times this is the time spread 
yi 
2𝑖𝜋𝑓𝑜𝑡 
13 
 
    is the frequency standard deviation, two times this is the frequency spread 
 The relationship between frequency standard deviation (  ) and time standard 
deviation (  )  is    
 
2   
⁄  
Example power calculation at 80 Hz using 10 cycles 
1. The wavelet with the above parameters is: (   2  )   ⁄     
  (   ) ⁄       (    )  
2. Convolution of signal with wavelet∫  ( )  (    )
 
  
 
3. Take the norm and square √(∫  ( )  (    ))
 
  
 
 
  (    )   ( )
   (    ) 
The following is a graphical overview of how data would be processed to calculate 
wavelet T/F outcomes. 
 
Figure 1.5.4b- Example EEG epoch trace 
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Figure 1.5.4c- Example EEG slice from epoch, the width of the EEG used will vary 
depending on frequency 
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Figure 1.5.4d- Wavelet transform equation applied to that slice 
 
 
Figure 1.5.4e- Definition of wavelet transform terms 
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Figure 1.5.4f- Outcome of one calculation 
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Figure 1.5.4g- Baseline saline plot completed from calculations 
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Figure 1.5.4h- Region averaged to obtain single gamma value 
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Figure 1.5.4i- Summary of process to obtain results 
1.6 Current validation of EEG measures against symptoms 
1.6.1 ERP components 
N1 latency delay is a robust electrophysiological endophenotype for autism, able 
to separate patients from non-patients (Roberts, Khan et al. 2010). In addition, there is 
evidence latency may be a predictor of language function (Oram Cardy, Flagg et al. 
2008). 
1.6.2 Gamma activity 
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Recent work has indicated that high-frequency (e.g., gamma) oscillations are 
particularly important as a biomarker for the treatment-resistant symptoms of 
schizophrenia (Gonzalez-Burgos, Fish et al. ; Sun, Farzan et al. ; Gandal, Edgar et al. 
2010; Uhlhaas and Singer 2010). Gamma oscillatory activity is known to be important for 
attention, working memory, sensory processing, and perceptual ‘feature binding’ – 
neurocognitive processes that are all disrupted in schizophrenia (Gandal, Edgar et al. 
2010). Indeed, one study reported a disruption in the phase-locked auditory-evoked 
gamma band response in schizophrenia patients that was correlated with reduced working 
memory capacity (Light 2006). Parvalbumin-expressing, fast-spiking interneurons – a 
sub-population of GABAergic cells disrupted in schizophrenia – have been shown to 
necessary and sufficient to generate gamma rhythms in vivo (Hashimoto, Volk et al. 
2003; Cardin, Carlen et al. 2009; Sohal, Zhang et al. 2009). There is preliminary evidence 
that pharmacologic reversal of gamma-band deficits in patients with schizophrenia is 
associated with clinical improvement in treatment-refractory domains (Lewis, Cho et al. 
2008). Finally, there is a wealth of evidence that the properties of gamma rhythms -- 
including frequency range, cross-frequency coupling, circuit generators, cortical function, 
and cognitive correlates – are phylogenetically conserved across mammals (and even 
invertebrates), making this an attractive biomarker for translational investigation (Gray 
and Singer 1989; Kirschfeld 1992; Brosch, Budinger et al. 2002; Buzsaki and Draguhn 
2004; Hall, Holliday et al. 2005; Colgin, Denninger et al. 2009; Sohal, Zhang et al. 2009). 
In summary, recent convergence of established signal processing techniques with 
the wealth of electrophysiological data, and an increase in understanding about the role of 
glutamate in psychiatric disease present new pathways for translational biomarker 
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development. The rest of this thesis examines acute NMDA antagonist administration 
models and selective KO of NMDARs on PV interneurons, examining the EEG changes 
present in each. It also explores some of the interrelationships between the measures, and 
relates some of the measures back to behavior. This thesis hopes to incrementally 
improve current understanding of glutamate disruption in disease and the ramifications it 
poses for brain circuits.   
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Chapter 2: NMDA Antagonists Recreate Signal-to-Noise Ratio and Timing 
Perturbations Present in Schizophrenia 
2.1 Abstract 
Rationale: There is increasing evidence that functional deficits in schizophrenia may be 
driven by a reduction in the signal-to-noise ratio (SNR) and consistent timing of neural 
signals. This study examined the extent to which exposure to the NMDA receptor 
antagonists ketamine and MK801, frequently used pharmacological models of 
schizophrenia, recreate deficits in electrophysiological markers of disturbed brain circuits 
that are thought to underlie the illness. Furthermore, this study characterizes the 
specificity of these differences across the frequency spectrum so as to help identify the 
nature of selective circuit abnormalities that mediate each oscillatory response as relevant 
to schizophrenia. 
Design: Mouse EEG was recorded during exposure to repeated auditory stimuli after 
injection of either vehicle or drug. The dose-response relationship for each 
electrophysiological measure was determined for ketamine and MK-801. Time-frequency 
analyses were performed to assess baseline, total, and evoked power and intertrial 
coherence (ITC) at low (5-10 Hz) and high (35-80 Hz)-frequencies. 
Results: High frequency evoked and total power was decreased by MK-801 and 
ketamine in a dose-dependent fashion. High frequency baseline power was increased by 
MK-801 and ketamine in a dose-dependent fashion. Similar to evoked power, high 
frequency inter-trial coherence was dose-dependently decreased by both drugs. Low 
frequency ITC was only decreased by ketamine. 
23 
 
Conclusions: Both ketamine and MK-801 cause alterations in  high-frequency baseline 
(noise), total (signal), and evoked (signal) power resulting in a loss of high frequency 
SNR that is thought to primarily reflect local circuit activity. These changes indicate an 
inappropriate increase in baseline activity, which can also be interpreted as non-task 
related activity. Ketamine induced a loss of intertrial coherence at low frequencies, 
indicating a loss of consistency in low-frequency circuit mechanisms. As a proportion of 
baseline power, both drugs had a relative shift from low to high frequencies, reflecting a 
change in the balance of brain activity from coordination of global regions to a pattern of 
discoordinated, autonomous local activity. These changes are consistent with a pattern of 
fragmented regional brain activity seen in schizophrenia. 
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2.2 Introduction 
Schizophrenia is a disabling psychiatric illness that affects about 1% of the 
population. Currently, there are no effective treatments for the negative and cognitive 
symptoms associated with this disease. Developing novel therapeutics for treatment 
resistant symptoms requires appropriate neural biomarkers associated with these deficits 
and valid animal models that reflect underlying disease pathophysiology. This study 
examined two pharmacologically-induced models of schizophrenia based on the 
glutamate hypothesis of disease pathogenesis, which is based on the observation that 
NMDA-receptor antagonists, such as ketamine, PCP, and MK801, have been shown 
clinically to induce psychosis and cognitive deficits indistinguishable from that seen in 
schizophrenia (Javitt and Zukin 1991). Additionally, administration of NMDA-receptor 
antagonists to model organisms has been demonstrated to recreate many of the cognitive, 
sensory, motor, and electrophysiological deficits seen in schizophrenia (Shiigi and Casey 
1999; Javitt, Jayachandra et al. 2000; Jackson, Homayoun et al. 2004; Swerdlow, Geyer 
et al. 2006). However, many of these preclinical studies have used ketamine to induce 
schizophrenia-like phenotypes, despite the fact that ketamine has many effects in addition 
to NMDA-receptor antagonism, such as activation of HCN1 channels, which make the 
causal interpretation of its effects more difficult (Chen, Shu et al. 2009). As such, this 
study investigated the effects of ketamine in addition to MK-801, a selective NMDA-
receptor antagonist, to compare the effects of these two drugs. Finally, to our knowledge, 
no studies have investigate the effects of either drug on auditory-evoked gamma-
frequency signal-to-noise, despite emerging evidence that this is an important biomarker 
for the treatment resistant symptoms of schizophrenia (Gandal, Edgar et al. 2010).  
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Studies from our group and others have shown a high degree of similarity 
between human and mouse EEG measures and auditory event-related potentials (ERPs) 
in terms of waveform morphology, as well as physiological and pharmacological 
response properties. These measures offer greater translatability than behavioral 
phenotypes as they can be investigated using the same auditory paradigms in preclinical 
and clinical studies, while giving responses with analogous components such as the 
P20/P50 and N40/N100 between mouse/human (Connolly, Maxwell et al. 2003; 
Umbricht, Vyssotky et al. 2004; Metzger, Maxwell et al. 2007). We have demonstrated 
that schizophrenia-like auditory-ERP deficits, such as reduced P1/N1 amplitude and 
habituation, can be recreated using pharmacological manipulations that disrupt 
neurotransmitter systems involved in schizophrenia pathophysiology, including 
dopamine, acetylcholine, and glutamate systems (Siegel, Maxwell et al. 2005; Maxwell, 
Ehrlichman et al. 2006; Phillips, Ehrlichman et al. 2007). Similar abnormalities have 
been demonstrated in transgenic mice with mutations in schizophrenia risk genes, 
including DTNBP1, NRG1, and GRIN1, which regulate glutamatergic signaling (Carlson, 
Talbot et al. ; Ehrlichman, Luminais et al. 2009; Halene, Ehrlichman et al. 2009).  
Recent work has indicated that high-frequency (e.g., gamma) oscillations are 
particularly important as a biomarker for the treatment-resistant symptoms of  
schizophrenia (Gonzalez-Burgos, Fish et al. ; Sun, Farzan et al. ; Gandal, Edgar et al. 
2010; Uhlhaas and Singer 2010). Gamma oscillatory activity is known to be important for 
attention, working memory, sensory processing, and perceptual ‘feature binding’ – 
neurocognitive processes that are all disrupted in schizophrenia (Gandal, Edgar et al. 
2010). Indeed, one study reported a disruption in the phase-locked auditory-evoked 
26 
 
gamma band response in schizophrenia patients, which was correlated with reduced 
working memory capacity (Light 2006). Parvalbumin-expressing, fast-spiking 
interneurons – a sub-population of GABAergic cells disrupted in schizophrenia – have 
been shown to necessary and sufficient to generate gamma rhythms in vivo (Hashimoto, 
Volk et al. 2003; Cardin, Carlen et al. 2009; Sohal, Zhang et al. 2009). There is 
preliminary evidence that pharmacologic reversal of gamma-band deficits in patients with 
schizophrenia is associated with clinical improvement in treatment-refractory domains 
(Lewis, Cho et al. 2008). Finally, there is a wealth of evidence that the properties of 
gamma rhythms -- including frequency range, cross-frequency coupling, circuit 
generators, cortical function, and cognitive correlates – are phylogenetically conserved 
across mammals (and even invertebrates), making gamma rhythms an attractive 
biomarker for translational investigation (Gray and Singer 1989; Kirschfeld 1992; 
Brosch, Budinger et al. 2002; Buzsaki and Draguhn 2004; Hall, Holliday et al. 2005; 
Colgin, Denninger et al. 2009; Sohal, Zhang et al. 2009). 
Since NMDA receptor antagonists have been able to recreate many of the 
cognitive, sensory, motor, and electrophysiological deficits of schizophrenia, these 
pharmacologic agents are among the leading methods for recreating schizophrenia-like 
deficits in animals (Shiigi and Casey 1999; Javitt, Jayachandra et al. 2000; Jackson, 
Homayoun et al. 2004; Swerdlow, Geyer et al. 2006). However, the electrophysiological 
consequences of disrupted glutamate signaling have only been studied for limited number 
of outcomes, P1, N1, P2, amplitude and latency as well as mismatch-negativity deficits 
following ketamine (Maxwell, Ehrlichman et al. 2006; Turetsky, Calkins et al. 2007; 
Amann, Halene et al. 2009). Furthermore, the mechanism by which  high-frequency 
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oscillations are perturbed by NMDA disruption is less studied, even though evidence 
suggests these oscillations reflect deficits in higher order cognitive functioning in 
schizophrenia (Light, Hsu et al. 2006). Therefore, it is important to understand how well 
these pharmacological models reflect the true endophenotypes of the disease in order to 
assess their face and predictive validity. This study examines how different NMDA 
antagonist agents influence low- and high-frequency oscillations to determine the extent 
to which they recreate the perturbations in SNR present in schizophrenia.  
For calculating SNR, morlet wavelets were used to create a time and frequency 
resolved map of event related spectral perturbations (ERSP), as shown in Figure 2.6.1A. 
This method allows evoked, baseline, and total power changes to be observed as they 
change in both the time and frequency domains in contrast to the traditional ERP and 
FFT methods that only have resolution in one domain. This enables more comprehensive 
analysis of transient stimulus related responses and by extension, understanding of neural 
circuit response. This method has been previously established in clinical studies of 
schizophrenia and autism and to examine power changes in those disorders. To evaluate 
the state of SNR in this model, baseline, evoked and total power were examined in high 
and low frequency ranges to determine if these two well established pharmacological 
models cause perturbations in the noise or stimulus-related signal similar to those found 
in schizophrenia (Hall, Taylor et al. ; Leicht, Kirsch et al. ; Reinhart, Mathalon et al. ; 
Lifshitz, Lee et al. 1987; Kessler and Kling 1991; Schellenberg and Schwarz 1993; 
Dierks, Strik et al. 1995; Jensen and Lisman 1996; Yamamoto 1997; Canive, Lewine et 
al. 1998; Kirino and Inoue 1999; Kwon, O'Donnell et al. 1999; Doheny, Faulkner et al. 
2000; Kissler, Muller et al. 2000; Koukkou, Federspiel et al. 2000; Behrendt 2003; 
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Krause, Hoffmann et al. 2003; Behrendt and Young 2004; Fujisawa, Matsuki et al. 2004; 
Hong, Summerfelt et al. 2004; Spencer, Nestor et al. 2004; Light, Hsu et al. 2006; Ford, 
Roach et al. 2008; Teale, Collins et al. 2008; Brenner, Kieffaber et al. 2009; Gaspar, 
Bustamante et al. 2009; Hall, Taylor et al. 2009; Krishnan, Hetrick et al. 2009). 
Additionally, inter-trial coherence, a measure for determining the trial to trial response 
consistency, was examined in low and high frequency regions to determine whether or 
not a loss of response consistency was associated with changes in power. This measure 
has also been used in clinical studies to examine deficits in circuit response timing in 
schizophrenia clinical trials. These measures will give a better understanding of the 
circuit disruptions driven by the NMDA system and how they match those found in 
schizophrenia. 
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2.3 Methods 
2.3.1 Subjects 
Forty-five male C57BL/6Hsd (B6) mice were obtained at 7–8 weeks of age from 
Jackson Labs (Bar Harbor, ME, USA). All testing was conducted between 10 and 18 
weeks of age. Mice were acclimated to the animal facility for 7 days before 
experimentation began and were housed four to five per cage until surgical implantation 
of the recording electrode, after which they were single-housed for the remainder of the 
study. All subjects were maintained in a standard 12-h light/dark cycle with free access to 
food and water. Experiments were performed during the light phase between 9:00 AM 
and 4:00 PM. All protocols were conducted in accordance with University Laboratory 
Animal Resources (ULAR) guidelines and were approved by the Institutional Animal 
Care and Use Committee (IACUC) at the University of Pennsylvania. All efforts were 
undertaken to minimize the number of animals used in the experiment and their suffering. 
2.3.2 Drugs and doses 
MK801 was obtained from Sigma-Aldrich (St. Louis, MO) and ketamine was 
obtained from Hospira (Lake Forest, IL). MK801 was dissolved in saline at doses of 0.1, 
0.4, 0.7, and 1 mg/kg prior to recording. Ketamine was dissolved in saline at doses of 5, 
10, 20, 40 mg/kg. All drugs and saline controls were administered via i.p. injection 5-10 
minutes prior to initiation of recording. 
2.3.3 EEG Recording 
Electrode Implantation 
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At 12 weeks of age, animals underwent stereotaxic implantation of electrode 
assemblies (PlasticsOne Inc., Roanoke, VA, USA) for non-anesthetized recording of 
auditory ERPs as previously reported (Connolly, Maxwell et al. 2003; Siegel, Connolly et 
al. 2003; Connolly, Maxwell et al. 2004; Maxwell, Liang et al. 2004). Animals were 
anesthetized with isoﬂurane and unipolar recording electrodes were placed in the CA3 
hippocampal region (1.8 mm posterior, 2.65 mm lateral and 2.75 mm deep relative to 
bregma) and referenced to the ipsilateral frontal sinus to reﬂect whole brain electrical 
activity. ERPs recorded from this electrode conﬁguration are characteristically similar to 
human recordings from the Cz scalp location as illustrated in a prior publication by our 
group (Siegel, Connolly et al. 2003). The electrode pedestal was secured to the skull 
using ethyl cyanoacrylate (Loctite, Henkel, Germany) and dental cement (Ortho Jet, Lang 
Dental, Wheeling, Illinois). EEG was recorded 1 week later, as described below. 
Electrophysiological Recordings 
EEG was recorded with Power1401 hardware and Spike6 software (CED, 
Cambridge, UK) as published previously (Ehrlichman, Gandal et al. 2009). A total of 
1000 white noise clicks were presented with a 1000 ms interstimulus interval at 85 dB.  
2.3.4 Frequencies analyzed and methods 
Intertrial coherence (ITC), evoked (total stimulus-related activity minus induced 
and baseline), baseline (pre-stimulus power), and event-related spectral perturbation 
(ERSP also known as  baseline corrected total power) values were calculated with Morlet 
wavelet decomposition using EEGLab (Delorme and Makeig 2004). Single-trial epochs -
250 and 750 ms relative to the auditory stimulus were extracted from the continuous data. 
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For each epoch (trial), the ITC, baseline power, evoked power, and baseline corrected 
total power were calculated at 75 linearly spaced frequencies from 5 to 80 Hz, with 
wavelet cycles increasing from 2 (at low frequencies) to 10 (at high frequencies). ITC is 
expressed as a unitless ratio between 0 and 1, where 1 represents complete phase 
synchrony at a given frequency and time across trials. Baseline, evoked, and total power 
were expressed in dB (10 * loguV^2). For each subject, high-frequency ITC and the 
power measures were calculated in a window around the peak evoked response, defined 
as the region from 0-60 ms poststimulus and from 35-80 Hz. The 0-60 ms range was also 
examined for perturbations in low frequency (5-10 Hz) activity. N40 amplitude was 
calculated from the ERPs as the difference between the lowest point between 30 and 80 
ms and the average of the baseline amplitude 50 ms pre-stimulus. 
2.3.5 Factor Analysis 
One way ANOVAs were performed to investigate the effect of each 
pharmacologic agent on EEG measures. Significant effects were followed by Tukey’s 
post-tests where appropriate. Factor analysis was performed using principle component 
analysis (PCA) on the individual subject data, examining the relationship between 
different measures across all drug and saline conditions. 
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2.4 Results 
Baseline EEG 
Baseline, pre-stimulus auditory-evoked EEG power was calculated at low and 
high frequencies using EEGLab. Both MK801 and ketamine dose-dependently increased 
baseline high-frequency power (MK801: F(1,4)=6.523, P=0.0001, ketamine: 
F(1,4)=11.92, P<0.0001) (Fig 2.6.2). MK801 and ketamine had no significant effects on 
baseline low frequency power. 
Post-stimulus Total Power 
Total power (e.g., event-related spectral perturbation, ERSP) was measured from 
0-60 ms following auditory stimuli using Morlet wavelet decomposition in EEGLab. 
MK-801 dose-dependently decreased total power at high frequencies (35-80 Hz) (Fig 
2.6.2 F(1,4)=15.15, P<0.0001). Ketamine had a similar effect, reducing high frequency 
total power (Fig 2.6.2; F(1,4)=18.48, p<0.0001) . MK801 and ketamine had no effect on 
low frequency total power.  
Post-Stimulus Evoked Power 
Evoked (e.g., phase-locked) power was calculated within the same time and 
frequency ranges. MK801 and ketamine reduced high-frequency evoked power (Fig 
2.6.3; MK801: F(1,4)=7.533 , P<0.0001, ketamine: F(1,4)=6.727, P<0.0001). 
Intertrial coherence (ITC) and evoked power are related measures that reflect the 
degree of phase-locking of an oscillation with a repeated external stimulus. ITC is 
thought to be a more pure measure of neural synchrony, however, as it is not biased by 
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the amplitude of an oscillation (CITE). Ketamine reduced low and high frequency ITC 
(low frequency ITC: F(1,4)=4.417, P=0.002, high frequency ITC: F(1,4)=7.573, 
P<0.0001). MK-801 did not change low frequency ITC but did reduce high-frequency 
ITC (Fig 2.6.4; F(1,4)=6.99, p<0.0001). 
N1 Amplitude 
Patients with schizophrenia have reduced auditory-evoked response amplitudes, 
especially for the N1 component, which is thought to reflect glutamatergic signaling 
(Dias, Butler et al. 2011). Validating that this effect was also present in our mouse 
models, MK801 and ketamine dose-dependently reduced N1/N40 amplitude. An 
ANOVA for the effects of each drug on N40 amplitude revealed that MK801 and 
ketamine significantly lowered N40 amplitude (Fig 2.6.5; MK801: F(1,4)=10.36, 
p<0.0001, ketamine: F(1.4)=15.01, p<0.0001). 
Signal-to-Noise Ratio (SNR) 
A change in SNR can be driven (1) a decrease in signal, (2) an increase in noise, 
or (3) both. In this study, decreased evoked and total power can be thought of as a 
reduction in signal, whereas increased baseline power likely reflects an increase in noise. 
To more explicitly calculate SNR, we divided post-stimulus evoked power by the 
preceding baseline levels in the same frequency range. As expected, both pharmacologic 
agents significantly reduced high frequency SNR, consistent with deficient sensory 
encoding (Fig 2.6.6; MK-801: F(1,4)=7.564, P<0.0001; ketamine: F(1,4)=7.57, 
P<0.0001). 
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Factor Analysis 
Factor 1 2 
High-frequency evoked power: 0.95 0.12 
High-frequency ITC: 0.35 0.60 
High-frequency baseline: -0.60 -0.11 
High-frequency baseline-corrected total power: 0.24 0.77 
Low-frequency ITC 0.13 0.77 
High-frequency SNR evoked: 0.96 0.12 
N40 amplitude from baseline: -0.01 -0.79 
Table 1: Factor analysis is used to understand the relationships between different 
variables within a dataset. Variables that concurrently have high loadings on the same 
factor indicate that they are related or depend on common causes. We separated the 
measures for all saline and drug conditions on to different factors using a threshold of 0.5 
for each factor loading, meaning one quarter the variance of each EEG measure can be 
accounted for by the factor. Using this process high-frequency evoked power, baseline 
power, and SNR grouped on factor 1. High-frequency and low-frequency coherence, 
high-frequency baseline-corrected total power, and N40 amplitude grouped together, on 
factor 2.  
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2.5 Discussion 
2.5.1 Comparison of Pharmacological Models to Schizophrenia 
Mice treated with MK-801 showed reductions in high-frequency evoked power, 
total power and intertrial coherence, similar to the deficits observed in schizophrenia 
(Koukkou, Federspiel et al. 2000; Roach and Mathalon 2008; Hall, Taylor et al. 2009; 
Krishnan, Hetrick et al. 2009). There was also an increase in high frequency baseline 
power similar to schizophrenia (Hong, Summerfelt et al. 2008). Unlike schizophrenia, 
there were no decreases in low-frequency evoked power, intertrial coherence, or 
increases in low-frequency baseline power (Kessler and Kling 1991; Schellenberg and 
Schwarz 1993; Canive, Lewine et al. 1998; Ford, Roach et al. 2008). Similarly, ketamine 
administration caused reductions in high-frequency intertrial coherence, evoked, and total 
power, along with decreased low frequency intertrial coherence, similar to findings 
reported in schizophrenia (Koukkou, Federspiel et al. 2000; Roach and Mathalon 2008; 
Hall, Taylor et al. 2009; Krishnan, Hetrick et al. 2009). Across drugs, we observed an 
increase in high frequency baseline power similar to schizophrenia (Hong, Summerfelt et 
al. 2008). In contrast, ketamine did not mimic the schizophrenia-like EEG signatures of 
reduced total low-frequency power, decreased low-frequency evoked power, and 
increased low-frequency baseline power (Kessler and Kling 1991; Nakagawa, Takeda et 
al. 1991; Schellenberg and Schwarz 1993; Canive, Lewine et al. 1998; Ford, Roach et al. 
2008). 
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Ketamine decreased low frequency intertrial coherence across trials, indicating 
reduced global consistency of response. Neither agent significantly changed baseline low 
frequency activity. With both agents, there was a reduction in high-frequency SNR 
caused by both a reduction of stimulus response signal and an increase in baseline noise. 
The relative increase in high compared to low frequency baseline activity reflects the 
shift from low to high frequencies reported in patients with schizophrenia. Taken 
together, these data suggest that disruption of NMDA-receptor mediated 
neurotransmission caused schizophrenia-like deficits in global coordination and 
consistency of responses.  
Factor analysis demonstrated the expected relationship between SNR and its 
constituent measures (factor 1). Factor analysis also indicated a pattern of disruptions in 
intertrial coherence, N40 amplitude reductions, and baseline-corrected total power (factor 
2) that could be hypothesized as a deficit in ability to mount a timely response to a salient 
stimulus. Furthermore, this analysis indicates that the SNR component parts vary 
independently of the timing measures. This could be thought of as two separate patterns 
of system disruption, one in the strength of the signal over noise, factor 1, and one in the 
timing of the response, factor 2. 
2.5.2 Potential Mechanisms for Specificity of Drug Effects 
The NMDA-receptor is a cation channel that produces excitatory postsynaptic 
potentials when activated and is important for learning and synaptic plasticity. Although 
both NMDA- receptor antagonists are non-competitive inhibitors, MK801 has a much 
lower reversibility than ketamine. Additionally, MK801 has 161 times the affinity of 
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ketamine, necessitating higher ketamine doses for similar drug effect (Wong, Kemp et al. 
1986). Unlike MK801, ketamine also has activity at mu opioid receptors, the targets of 
morphine and codeine among other opiates, as well as at HCN channels that are thought 
to mediate its anesthetic effect. Furthermore, administration of mu-opioid receptor 
targeting drugs alters low frequency EEG (Greenwald and Roehrs 2005). Therefore, high 
doses of ketamine may be altering low frequency oscillations via the mu-opioid receptor, 
while MK-801 may provide more specific activity at NMDA-receptors. 
2.5.3 Limitations and Future Directions 
The current study employed acute MK-801 and ketamine administration. 
Alternatively, chronic administration may have resulted in a different pattern of deficits. 
This is relevant as schizophrenia is thought to be a chronic developmental disease, in 
which both reduced NMDA- receptor function and compensatory changes likely 
contribute to observed phenotypes. This limitation is more applicable to ketamine where 
repeated administration is required for PV interneuron disruption as opposed to MK801 
where only a single dose is required (Romon, Mengod et al. ; Behrens and Sejnowski 
2009). 
This study limited its EEG analysis to the region 60 ms post-stimulus. While there 
are relevant changes outside this range reported, this study focused its analysis to the 
obligatory ERP region and EEG changes related to that range (Gallinat, Winterer et al. 
2004). This allowed for more cohesive analysis of a constellation of related features, and 
an examination of the relationship between these early related features. 
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In addition, it would be preferable to know the relative disruption of interneurons 
and pyramidal cells following NMDA-receptor blockade, however it is not possible to 
quantify that distribution using the systemic administration drug model. Some have 
suggested that there are brain region specific differences in high-frequency activity when 
treated with NMDA antagonists (Roopun, Cunningham et al. 2008). Although this has 
been noted in slices, in-vivo data suggests that the disruption is generalized (Hakami, 
Jones et al. 2009). There are many possible reasons for these apparently disparate results, 
many likely arising from the confounds inherent in slice work where physiologic 
conditions and connections are difficult to replicate. In addition, while similar results 
were recently published in human subjects following ketamine exposure, we believe this 
strengthens the current work by showing consistency across species after administration 
of similar drugs (Hong, Summerfelt et al. 2010). We have also extended previous work 
by performing multi-factor analysis between the different disruptions of neural circuit 
operations and additionally used a more specific NMDA antagonist, MK-801, to confirm 
that the cause of the disruptions is primarily glutamate related. 
Despite these potential limitations, the current study suggests that a reduction of 
NMDA-receptor signaling contributes to the pattern of reduced high-frequency SNR 
observed in schizophrenia, as well as the shift from low frequency to high frequency 
activity in schizophrenia. These changes are consistent with the hypothesis that 
schizophrenia is characterized by a functional disconnection of distant brain regions, with 
a coincident increase in autonomous, local activity (Schmitt, Hasan et al.).  
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2.6 FIGURE LEGENDS 
Figure 2.6.1- Overview of Frequency Measures 
 
Grand-Average Time-Frequency Plots of 0.7 mg/kg MK801.  The effect of MK801 on 
auditory-evoked power and intertrial coherence (ITC) is shown. A) Event-related spectral 
perturbation (e.g., ERSP, in dB relative to pre-stimulus-baseline) is demonstrated for 
saline and MK-801 (0.7 mg/kg) conditions. The right panel shows statistically different 
time-frequency regions (P<0.05).  B) Intertrial coherence (e.g., ITC) is plotted across 
time and frequency for saline and MK-801 conditions. The right plot highlights 
statistically different regions (P<0.05). 
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Figure 2.6.2- High Frequency Total and Pre-stimulus Power 
 
Effects on total and baseline power in the high frequency range following ketamine 
and MK-801. A) Total high-frequency power was dose-dependently reduced following 
both ketamine and MK-801. B) Both agents dose-dependently increased high-frequency 
baseline power, which can be thought of as non-task related activity or noise if it was 
increased over the reference state. Figures show mean + S.E.M. (*** P<0.001) 
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Figure 2.6.3- High Frequency Evoked Power 
 
Effects on high-frequency evoked power following ketamine and MK-801 
administration. Both agents dose-dependently reduced high-frequency evoked power, 
which can be thought of as the specific signal response to an external stimulus.  Figures 
show mean + S.E.M. (**P<0.01, *** P<0.001) 
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Figure 2.6.4- High and Low Frequency ITC 
 
Effects of ketamine and MK-801 on low and high-frequency intertrial coherence.  
Both ketamine and MK-801 dose-dependently reduced high and low-frequency ITC 
which measures the precision of response timing in the brain. Figures show mean +/- 
S.E.M. (**P<0.01, *** P<0.001) 
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Figure 2.6.5- N40 Amplitude Changes 
 
Effects on N40 amplitude following ketamine and MK-801 administration. Both 
agents dose-dependently reduced N40 amplitude, replicating previous studies of NMDA-
receptor antagonists and consistent with EEG results observed in schizophrenia patients.  
Grand average saline ERP shown on left. Figures show mean + S.E.M. (**P<0.01, *** 
P<0.001) 
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Figure 2.6.6- SNR Evoked 
 
Signal-to-noise ratio (SNR) as calculated by evoked power divided by baseline 
activity.  Both ketamine and MK-801 dose-dependently decreased high-frequency SNR 
as defined by the ratio of evoked power divided by prestimulus baseline power.  Figures 
show mean +/- S.E.M. (**P<0.01, *** P<0.001) 
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Chapter 3: NMDA antagonist MK-801 recreates auditory electrophysiological 
disruptions present in autism 
3.1 Abstract 
Autism is a highly disabling neurodevelopmental disorder characterized by social 
deficits, language impairment, and repetitive behaviors. There are few effective 
biological treatments for this disorder, partly due to the lack of translational biomarkers.  
However, recent data suggest that autism has reliable electrophysiological 
endophenotypes, along with evidence that some deficits may be caused by NMDA 
receptor (NMDAR) dysfunction.  Similarly, the NMDAR antagonist MK-801 has been 
used in behavioral animal models of autism.  Since MK801 has also been used as a model 
of schizophrenia, this paper examines the independent and overlapping ways in which 
MK-801 recreates the electrophysiogical changes present in both diseases. Mouse EEG 
was recorded in response to auditory stimuli after either vehicle or MK-801 and the dose-
response relationship for each measure was determined.  ERP component amplitude and 
latency analysis was performed along with time-frequency analysis of gamma frequency 
inter-trial coherence and evoked power. Evoked gamma power and ITC were decreased 
by MK-801 at the highest dose.  P1 and N1 latency were increased in dose dependent 
fashion following MK-801.  There were no amplitude changes in P1 or N1.  MK801 
caused alterations in evoked gamma activity, gamma ITC, P1 and N1 latency similar to 
findings in autism. These data provide evidence indicating that NMDAR dysfunction 
may contribute to deficits specific to autism and some that overlap with other disorders 
such as schizophrenia.  Such observations could be important for developing novel 
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therapeutics, as electrophysiological endophenotypes are associated with functional 
measures and therefore may provide early biomarkers for efficacy in clinical trials. 
3.2 Introduction 
Autism spectrum disorders (ASD) are characterized by deficits in social, 
cognitive, and language function.  Despite emerging evidence for genetic and molecular 
contributions to the disorder, behavioral measures remain the primary method of 
diagnosis.  However, electrophysiological and neural biomarkers could potentially 
provide robust measures to quantify the degree of impairment and provide more focused 
guidance for treatment development (Edgar JC 2007).  These measures have advantages 
in their translatability between mice and humans.  For instance, human auditory evoked 
responses have a P50 (P1) and N100 (N1) which display similar morphology and drug 
responses as the mouse P20 (P1) and N40 (N1) (Amann, Gandal et al. 2010).  These 
measures can also be examined using magnetoencephalography (MEG) which has 
magnetic analogues including the M50 and M100.  In addition, there is evidence that 
gamma inter-trial coherence and evoked power are related to similar cognitive and 
sensory processes across species (Gandal, Edgar et al. 2011). 
Several recent findings provide guidance for pre-clinical model development for 
ASD.  First, genetic and postmortem studies indicate that the pathophysiology of ASD 
may include a component of NMDA receptor (NMDAR) disruption (Bangash, Park et al. 
2011).  Additional support for this idea has been provided by studies using MK-801 to 
recreate autism-like behavioral deficits in mice (Wu, Zou et al. 2005; Zou, Zhang et al. 
2008).  Studies in children with ASD using MEG have elucidated novel neural 
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biomarkers for the disorder which could be translated into animal EEG models (Roberts, 
Khan et al. 2010).  Speciﬁcally, children with ASD show a delay in the M100 in superior 
temporal gyrus (STG), with this latency prolongation providing a high degree of accuracy 
for ASD classiﬁcation.  There is also evidence that neural synchrony is disturbed in ASD, 
particularly in the gamma-band (Gandal, Edgar et al. 2010).  Such oscillations are 
important for sensory integration and functional connectivity, which are disrupted in 
ASD (Sohal, Zhang et al. 2009).  There is also evidence that P1 and N1 latency are 
predictive of language impairment (Oram Cardy, Flagg et al. 2008; Roberts, Cannon et 
al. 2011). 
The current study examines a potential pre-clinical model for several types of 
electrophysiological biomarkers, P1 and N1 latency prolongation, reduced gamma inter-
trial coherence and gamma evoked power, following exposure to a NMDAR antagonist.  
We propose that quantifying the extent to which clinical ASD markers are recapitulated 
in this model will be a critical step towards evaluating its predictive validity for 
therapeutic development.  This is important because NMDAR disruption models have 
also been closely linked to schizophrenia, another disabling but distinct disease.  For 
example, gamma inter-trial coherence and evoked power disruptions have been shown in 
both diseases.  In contrast, there is evidence that P1 and N1 latency is increased in ASD, 
while most studies in schizophrenia have shown no change in either latency (Hanlon, 
Miller et al. 2005).  Alternatively, N1 amplitude is reduced in schizophrenia, but remains 
unaffected in ASD (Roberts, Khan et al. 2010; Mazhari, Price et al. 2011).  Therefore, 
parsing which aspects of the model map to ASD versus schizophrenia are important for 
48 
 
determining the precise mechanisms of deficit, and corresponding therapeutic approaches 
in the different disorders. 
The MK801 dose-response relationship to schizophrenia- and autism-like 
symptoms may be related to the degree of glutamate signaling disruption in each 
disorder.  We observed that low levels of MK801 caused EEG changes that are more 
autism-like with delays in P1 and N1 latency accompanied by reduced gamma coherence 
and evoked power.  Alternatively, high dose MK801 caused reductions in N1 amplitude, 
gamma inter-trial coherence, and evoked power, similar to schizophrenia (Saunders, 
Gandal et al. 2012).  Such findings suggest a common glutamatergic circuit disruption in 
ASD and schizophrenia that varies in degree. 
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3.3 Methods 
3.3.1 Subjects 
Fifteen male C57BL/6Hsd (B6) mice were obtained from Jackson Laboratories at 
7–8 weeks of age.  All testing was conducted between 10 and 18 weeks of age.  Mice 
were acclimated to the animal facility for at least 7 days before experimentation began 
and were housed four to five per cage until implantation of the recording electrode, after 
which they were single-housed for the remainder of the study.  All subjects were 
maintained in a standard 12-h light/dark cycle with free access to food and water.  
Experiments were performed during the light phase between 9:00 AM and 4:00 PM.  All 
protocols were conducted in accordance with University Laboratory Animal Resources 
(ULAR) guidelines and were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Pennsylvania.  All efforts were undertaken to 
minimize the number of animals used in the experiment and their suffering. 
3.3.2 Drugs and doses 
MK801 was obtained from Sigma-Aldrich (St. Louis, MO).  MK801 was used at 
doses of 0.1, 0.2, 0.3, and 0.4 mg/kg i.p.  All drugs and saline controls were administered 
5-10 minutes prior to initiation of recording.  MK801 has a half-life of two hours in 
rodents, ensuring consistent drug effect over a recording session. 
3.3.3 EEG Recording 
Electrode Implantation: At 12 weeks, animals underwent stereotaxic 
implantation of a stainless steel tripolar electrode assembly (Plastics1, Roanoke, Virginia) 
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as published (Gandal, Ehrlichman et al. 2008).  Animals were anesthetized with 
isoflurane, and a low-impedance (5 k, 1000 Hz) macro-electrode was stereotaxically 
positioned between auditory cortex and auditory thalamus (1.8 mm posterior, 2.65 mm 
lateral, 2.75 mm deep relative to bregma) and referenced to frontal sinus.  This 
configuration captures both early and late components of the auditory evoked potential 
(AEP), including the midlatency P20 (e.g., human P50/M50) and N40 (e.g., human 
N100/ M100) (Siegel, Connolly et al. 2003).  The electrode pedestal was secured to the 
skull using ethyl cyanoacrylate (Loctite, Henkel, Germany) and dental cement (Ortho Jet, 
Lang Dental, Wheeling, Illinois).  EEG was recorded 1 week later, as described below. 
Electrophysiological Recordings: EEG was recorded with Micro1401 hardware 
and Spike6 software (CED, Cambridge, UK) as published previously (Ehrlichman, 
Gandal et al. 2009).  A total of 250 white noise clicks were presented with a 4 s 
interstimulus interval at 85 dB. 
3.3.4 Frequencies analyzed and methods 
Electrophysiology Analysis: The amplitude and latency were calculated for P1 
(defined as the most positive deflection between 10 and 40 ms) and N1 (defined as the 
most negative deflection between 30 and 200 ms).  These regions are important because 
the characteristic positive and negative deﬂections of the EEG recording occur at 
approximately 40% the latency but similar morphology to the equivalent human 
components (Siegel, Connolly et al. 2003; Umbricht, Vyssotky et al. 2004).  Therefore, 
the P20 and N40represent ERP deﬂections in mice analogous to the P50 and N100, 
respectively, in humans (Amann, Gandal et al. 2010). 
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Inter-trial coherence (ITC), evoked power (total power minus induced and 
baseline power), baseline (total power occurring -100 to -400 ms prestimulus), and 
baseline corrected total power (total power poststimulus minus baseline) values were 
calculated with Morlet wavelet decomposition using EEGLab (Delorme and Makeig 
2004).  In particular, single-trial epochs -250 and 750 ms relative to the auditory stimulus 
were extracted from the continuous data.  For each epoch (trial), the ITC, baseline power, 
evoked power, and baseline corrected total power were calculated using 69 linearly-
spaced frequencies from 12 to 80 Hz, with wavelet cycles increasing from 2 (at low 
frequencies) to 10 (at high frequencies).  ITC is expressed as a unitless ratio between 0 
and 1, where 1 represents complete phase synchrony at a given frequency and time across 
trials.  Evoked, baseline, and baseline corrected total power was expressed in dB (10 
log10).  For each subject, the ITC and power measures were calculated in a window 
around the peak gamma response, defined as the region from 0-60 ms poststimulus and 
from 30-80 Hz.  In addition, P1 and N1 latency was calculated in milliseconds after 
stimulus. 
Statistical Analysis: Repeated measures ANOVAs were performed to investigate 
the effect of each pharmacologic agent on EEG measures.  Significant effects were 
followed by Tukey’s post-tests where appropriate. 
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3.4 Results 
N1 latency changes had a significant positive association with dose of MK-801 
(Fig 1 P<0.0001, F(4,56)=8.657).  P1 latency changes had a significant positive 
association with dose of MK-801 (Fig 2 P<0.0001, F(4,56)=9.855).  Gamma inter-trial 
coherence (Fig 3 P<0.001, F(4,56)=5.738) and evoked gamma power (Fig 3 P<0.001, 
F(4,56)=5.372) had a significant negative relationship with MK-801 dose.   
After Tukey’s post-test for multiple comparisons, there were significant 
differences in N1 latency between saline and 0.2, 0.3, or 0.4 mg/kg MK-801 conditions 
(P<0.05).  There were significant differences in P1 latency between saline and 0.2, 0.3. 
0.4 mg/kg MK-801 conditions.  There were significant differences in gamma inter-trial 
coherence and evoked power between saline and 0.4 mg/kg MK-801 along with 0.1 
mg/kg and 0.4 mg/kg MK-801 (P<0.01) conditions. 
There were no significant associations between dose and P1 or N1 amplitude 
(P=0.8553, P=0.1703). 
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3.5 Discussion 
The current study demonstrates that P1 latency, N1 latency, evoked gamma power 
and gamma inter-trial coherence changes following MK-801 mimic electrophysiological 
endophenotypes of ASD.  N1 latency delays of 10% matched those found in ASD MEG 
studies which in turn were able to discriminate between patients and controls (Gandal, 
Edgar et al. 2010; Roberts, Khan et al. 2010).  The ERP alterations following MK-801 
were specific to P1 and N1 latency, with no amplitude changes observed for P1 or N1 
components, also similar to findings in ASD.  In addition, while latency changes are 
small, significant differences existed because measurements had very low variability, 
indicating tight physiological control of response latency.  These electrophysiological 
data are consistent with previous studies in which MK-801 has been used to model the 
core deficits of ASD in rodents including stereotypies, social deficits and withdrawal 
(Wu, Zou et al. 2005; Zou, Zhang et al. 2008). 
One limitation of the current study is that the disruptions in gamma inter-trial 
coherence and evoked power disruptions match recordings done in ASD, but are also 
present in schizophrenia.  Similarly, stereotypies, social deficits and withdrawal created 
by MK-801 are also found in schizophrenia (Burket, Cannon et al.).  Qualitative, but 
nonsignificant reduction of N1 amplitude was found in the current data set, consistent 
with the direction but not extent of changes in schizophrenia.  Additionally, drugs like 
MK-801 and phencyclidine (PCP) can induce pre-pulse inhibition (PPI) deficits and 
hyperlocomotion at the doses tested, indicating that deficits are not selectively tied to 
social function.  Thus, MK-801 is not specific as a model of ASD and   reduced 
NMDAR-mediated glutamate transmission appears to model the overlap between ASD 
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and schizophrenia. It therefore may be helpful in determining the common, rather than 
distinguishing aspects of their pathophysiology. 
The pattern of endophenotypes that are shared by schizophrenia and ASD 
illustrate the relative extent of glutamatergic contributions towards the two disorders (Fig 
4).  There is evidence to suggest that both disorders have a glutamate component and 
several studies have shown a connection between autism-like symptoms and glutamate 
disruption.  For example, Anti-NMDA receptor encephalitis has been reported to mimic 
late onset autism (Creten, van der Zwaan et al. 2011).  Additionally, glutamate has been 
shown to be related to interpersonal skills (Montag, Schubert et al. 2008).  This may 
indicate that there are localized areas of glutamatergic dysfunction in ASD that give rise 
to the change in electrophysiological response latencies, gamma coherence, and gamma 
evoked power without psychosis.  In contrast, the glutamatergic dysfunction of 
schizophrenia may be the driver of psychosis, negative symptoms, and cognitive deficits.  
Another possible hypothesis is that low levels of glutamatergic disruption may be more 
ASD like, while greater dysfunction is more schizophrenia like.  The qualitative but non-
significant reduction in N1 at the MK-801 dosages used supports this view because 
higher doses have previously been reported to reduce N1 amplitude similar to those 
found in schizophrenia (Saunders, Gandal et al. 2012).  However, P1 and N1 latency 
changes are typically not reported in schizophrenia, suggesting the electrophysiological 
disruptions may be from different domains.  Given that patients with schizophrenia have 
EEG timing deficits, as measured by ITC, and that latency shifts in the current study and 
ASD are significant because their variability is extremely low, the reduction in 
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consistency of EEG response timing in schizophrenia may mask any changes in latency 
from being measured. 
In summary, the current study indicates that acute pharmacological disruption of 
NMDAR signaling recapitulates several aspects of ASD, as well as those of 
schizophrenia.  Furthermore, previous studies suggest that the electrophysiological 
endophenotypes induced by MK-801 are linked to functional measures in both ASD and 
schizophrenia, this model may be useful for testing novel therapeutics for language 
impairment among other targets (Oram Cardy, Flagg et al. 2008). For example, 
behavioral effects of NMDA disruption have been reversed with mGluR5 agonist MPEP.  
Similar findings in future electrophysiological and behavioral studies could suggest that 
reversal EEG deficits would provide an early indication that novel compounds could be 
effective in autism and/or schizophrenia. 
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3.6 FIGURE LEGENDS 
Figure 3.6.1- N1 Latency 
 
N1 latency was examined following MK-801 at 0.1, 0.2, 0.3, 0.4 mg/kg.  There was a 
significant relationship between increasing MK-801dose and longer N1 latency.  This 
increase in N1 latency is similar to the pattern found for the corresponding M100 in 
children with ASD using MEG. Figure shows mean + SEM (* P<0.05, ** P<0.01, *** 
P<0.001 after Tukey’s test for multiple comparisons between saline and conditions). 
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Figure 3.6.2- P1 Latency 
 
P1 latency was examined following MK-801 at 0.1, 0.2, 0.3, 0.4 mg/kg.  There was a 
significant relationship between increasing MK-801dose and longer P1 latency.  This 
increase in P1 latency is similar to the pattern found for the corresponding M50 in 
children with language impairment using MEG. Figure shows mean + SEM (* P<0.05, 
*** P<0.001 after Tukey’s test for multiple comparisons between saline and conditions).  
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Figure 3.6.3- Gamma ITC and Evoked Power 
 
Gamma ITC and evoked power was examined following exposure to MK-801 at 0.1, 0.2, 
0.3, and 0.4 mg/kg.  There was a significant relationship between increasing dose of MK-
801and reduction in gamma ITC and evoked power.  Thus, MK-801 recapitulates the 
overlapping pattern of reduced gamma ITC and evoked power found among patients with 
either ASD or schizophrenia.  Figure shows mean + SEM (** P<0.01 *** P<0.01 after 
Tukey’s test for multiple comparisons between saline and conditions). 
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Figure 3.6.4- Overlapping Symptoms and EEG Profile 
 
Graphical illustration of the continuum of EEG and behavioral deficits along different 
doses of MK-801.  The autism specific and overlapping with schizophrenia phenotypes 
are elucidated at the doses used in this study. (1) (Zou, Zhang et al. 2008) (2) (Ninan and 
Kulkarni 1998) (3) (Ralph-Williams, Lehmann-Masten et al. 2002) (4) (de Oliveira, 
Dall'Igna et al. 2005) (5) (Saunders, Gandal et al. 2012) 
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Chapter 4: Knockout of NMDA Receptors in Parvalbumin Interneurons Recreates 
Autism like Phenotypes 
4.1 Abstract 
Autism is a disabling neurodevelopmental disorder characterized by social 
deficits, language impairment, and repetitive behaviors with few effective treatments. 
New evidence suggests that autism has reliable electrophysiological endophenotypes, and 
that these measures may be caused by NMDA receptor (NMDAR) disruption on 
Parvalbumin (PV) containing interneurons. These findings could be used to create new 
translational biomarkers. Recent developments have allowed for cell-type selective 
knockout of NMDA receptors in order to examine the perturbations caused by disrupting 
specific circuits. This study examines several electrophysiological and behavioral 
measures disrupted in autism using a PV-selective reduction in NMDA R1 subunit. 
Mouse EEG was recorded in response to auditory stimuli. Event related potential (ERP) 
component amplitude and latency analysis, social testing and pre-mating ultrasonic 
vocalizations (USV) recordings were performed. Correlations were examined between 
the ERP latency and behavioral measures. The N1 ERP latency was delayed, sociability 
was reduced and mating USVs were impaired in PV-selective NR1 KO as compared to 
Wild type (WT) mice. There was a significant correlation between N1 latency and 
sociability, but not between N1 latency and premating USV power or T-maze 
performance. The increases in N1 latency, impaired sociability and reduced vocalizations 
in PV-selective NR1 KO mice mimic similar changes found in autism. 
Electrophysiological changes correlate to reduced sociability indicating the local circuit 
mechanisms controlling N1 latency may be utilized in social function. Therefore, we 
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propose that behavioral and electrophysiological alterations in PV-selective NR1 KO 
mice may serve as a useful model for therapeutic development in autism. 
4.2 Introduction 
Autism spectrum disorders (ASD) are characterized by deficits in social, 
cognitive, and language function. Despite sustained efforts, many of the deficits remain 
recalcitrant to treatment. One reason for the lack of effective treatments is the lack of 
predictive translational disease models. Therefore, having more predictive models that 
recreate the behavioral and electrophysiological changes present in autism would help aid 
development of new therapeutics. 
 
Several recent findings provide guidance for pre-clinical model development for 
ASD. First, genetic and postmortem studies indicate that the pathophysiology of ASD 
may include a component of NMDA receptor (NMDAR) disruption (Bangash, Park et al. 
2011). Studies in children with ASD using magnetoencephalography (MEG) have 
elucidated novel neural biomarkers for the disorder, which could be translated into 
animal EEG models (Roberts, Khan et al. 2010). Speciﬁcally, children with ASD show a 
delay in the M100 in superior temporal gyrus (STG), with this latency prolongation 
providing a high degree of accuracy for ASD classiﬁcation. There is also evidence that 
these electrophysiological markers are predictive of language impairment (Oram Cardy, 
Flagg et al. 2008; Roberts, Cannon et al. 2011).  
 
EEG measures could potentially provide behavior-independent biomarkers that 
quantify the degree of impairment along with providing more focused guidance for 
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treatment development (Edgar JC 2007). These measures have advantages in their 
translatability between mice and humans. For instance, human auditory evoked responses 
have a P50 (P1) and N100 (N1) which display similar morphology and drug responses as 
the mouse P20 (P1) and N40 (N1) (Amann, Gandal et al. 2010). These measures can also 
be examined using MEG, which has magnetic analogues including the M50 and M100. 
 
In addition, animal models of social behaviors have been developed as 
translational platforms for examining human sociability. The social choice task, examines 
the preference of a test mouse for same sex mouse, as compared to an inanimate object. 
Given the reduced preference for social interactions in autism, this task attempts to model 
such behaviors. Additionally there are typically language impairments in patients with 
autism. In mice, one model of this language impairment is examining the characteristic 
patterns of 70 kHz ultrasonic pre-mating vocalizations. In this task, a male mouse that is 
exposed to a target female will vocalize at 70 kHz prior to mating. 
 
The current study examines a potential pre-clinical model for characteristic 
autism-like alterations in N1 latency, sociability, and situation-appropriate (pre-mating) 
USVs. We propose that quantifying the extent to which clinical ASD markers are 
recapitulated in this model will be a critical step towards evaluating its predictive validity 
for therapeutic development. This is important because NMDAR disruption models have 
also been closely linked to schizophrenia, another disabling but distinct disease (Javitt, 
Jayachandra et al. 2000). Although NMDA receptor signaling is also implicated in 
autism, there are several distinctions in the patterns of EEG abnormalities in each 
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disorder. For example, there is consistent evidence that N1 latency is increased in ASD, 
while most studies in schizophrenia have shown no change in N1 latency (Hanlon, Miller 
et al. 2005). Alternatively, N1 amplitude is reduced in schizophrenia, but remains 
unaffected in ASD (Roberts, Khan et al. 2010; Mazhari, Price et al. 2011). 
 
Previous studies suggest that systemic administration of NMDA receptor 
antagonists and non-specific genetic disruption of NMDA receptor signaling leads to an 
overall increase in EEG activity (Fitzgerald 2012). It has been widely proposed that this 
increase in activity represents a selective reduction of excitatory drive on interneurons 
(Gonzalez-Burgos and Lewis 2012). However, the cellular specificity of this response has 
not been directly tested. The current study tests the hypothesis that reduction of NMDA 
receptor activity only in PV containing interneurons will disrupt circuits involved in mid-
latency evoked response regulation. Furthermore, the observed alterations will be related 
to behavioral phenotypes that are relevant to ASD. 
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4.3 Methods 
4.3.1 Subjects 
Homozygous Parvalbumin-cre/cre mice (B6;129P2-Pvalb
tm1(cre)Arbr
/J) as well as a 
homozygous NMDA-Receptor1-flox/flox mice (B6.129S4-Grin1
tm2Stl
/J) were purchased 
from The Jackson Laboratory (Bar Harbor, Maine). Homozygous parvalbumin-cre/cre 
(PV-cre/cre) mice were bred with homozygous NMDA-receptor1-flox/flox (NR1-fl/fl) 
mice. The offsprings, heterozygous PVcre/+;NR1-fl/+, were backcrossed with 
homozygous PV-cre/cre mice in order to obtain mice homozygous PV-cre/cre and 
heterozygous NR1-fl/+. The PV-cre/cre;NR1-fl/+ mice were then crossed with one 
another in order to obtain the following genotypes: PV-cre/cre;NR1fl/fl (referred to as 
PV-selective NR1 KO), PV-cre/cre;NR1-+/+ (referred to as wild type or WT). These 
mice have been characterized in a previous publication by Carlen et al (Carlen, Meletis et 
al. 2011). All testing was conducted between 10 and 18 weeks of age. Mice were 
acclimated to the animal facility for at least 7 days before experimentation began and 
were housed four to five per cage until implantation of the recording electrode, after 
which they were single-housed for the remainder of the study. All subjects were 
maintained in a standard 12-h light/dark cycle with free access to food and water. 
Experiments were performed during the light phase between 9:00 AM and 4:00 PM. All 
protocols were conducted in accordance with University Laboratory Animal Resources 
(ULAR) guidelines and were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Pennsylvania. All efforts were undertaken to 
minimize the number of animals used in the experiment and their suffering. 
4.3.2 Behavioral Methods 
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Sociability Testing: We previously demonstrated that constitutive reduction of 
NMDAR1 and the NMDA receptor related protein Neuregulin 1 (NRG1) result in 
reduced social interactions (Ehrlichman, Luminais et al. 2009; Halene, Ehrlichman et al. 
2009). As such, we and others have suggested that impaired NMDAR signaling may 
contribute to social deficits in autism. Social interactions were assessed as previously 
published (Ehrlichman, Luminais et al. 2009). 
 
T-maze: PV-selective NR1 KO and WT mice were assessed for working memory 
function according to published methods for discrete T-maze (Deacon and Rawlins 
2006). Data were collected using a 1 second delay, which has been shown to require 
hippocampal, as well as frontal contributions. Unpaired t-tests were used to compare 
effects between groups. 
4.3.3 EEG Methods 
Electrode Implantation: At 12 weeks of age, animals underwent stereotaxic 
implantation of a stainless steel tripolar electrode assembly (Plastics1, Roanoke, Virginia) 
as published (Gandal, Ehrlichman et al. 2008). Animals were anesthetized with 
isoflurane, and a low-impedance (5 k, 1000 Hz) macro-electrode was stereotaxically 
positioned between auditory cortex and auditory thalamus (1.8 mm posterior, 2.65 mm 
lateral, 2.75 mm deep relative to bregma) and referenced to frontal sinus. This 
configuration captures both early and late components of the auditory evoked potential 
(AEP), including the midlatency P1, (human P50/M50) and N1 (human N100/ M100) as 
published (Siegel, Connolly et al. 2003). The electrode pedestal was secured to the skull 
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using ethyl cyanoacrylate (Loctite, Henkel, Germany) and dental cement (Ortho Jet, Lang 
Dental, Wheeling, Illinois). EEG was recorded 1 week later, as described below. 
 
Electrophysiological Recordings: EEG was recorded with Micro1401 hardware 
and Spike6 software (CED, Cambridge, UK) as published previously (Ehrlichman, 
Gandal et al. 2009). A total of 200 white noise clicks were presented with an 8 second 
interstimulus interval at 85 dB.  
 
Electrophysiology Analysis: The amplitude and latency were calculated for P1 
(defined as the most positive deflection between 10 and 30 ms) and the N1 (defined as 
the most negative deflection between 30 and 80 ms). These components of the mouse 
ERP recording occur at approximately 40% the latency but occur with similar 
morphology, pharmacology and psychophysiology to the equivalent human components 
(Siegel, Connolly et al. 2003; Umbricht, Vyssotky et al. 2004). Therefore, the P1, and N1 
represent ERP deﬂections in mice analogous to the P50, and N100 in humans (Amann, 
Gandal et al. 2010). Amplitude was calculated relative to zero, and latency was calculated 
in milliseconds after stimulus onset. 
4.3.4 USV Methods 
USV Testing: Adult mice do not emit ultrasonic vocalizations spontaneously, but 
do so when placed in certain contexts involving social interaction (Scattoni, Crawley et 
al. 2009). When paired with a female mouse, male mice will emit “pre-mating” and 
“mating” vocalizations (Ricceri, Moles et al. 2007). During the pre-mating phase prior to 
mount, the male emits predominantly 70 kHz vocalizations. 
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For the adult mating paradigm, the test mouse was paired with an unfamiliar, 
sexual-receptive female wildtype mouse in a clean cage within a sound attenuated 
chamber for 5 minutes, as has been investigated in other mouse models of ASDs (Jamain, 
Radyushkin et al. 2008). For the mating task, USVs were recorded with an ultrasonic-
range microphone suspended 10 cm above the cage. 
 
USV Analysis: Data from ultrasonic vocalization paradigms were analyzed 
according to spectral power of the calls, as previously done (Maggio and Whitney 1985; 
White, Prasad et al. 1998; Gourbal, Barthelemy et al. 2004; Ricceri, Moles et al. 2007). 
Spectral analysis was done as follows. Vocalization data were analyzed in the frequency 
domain by computing the FFT of the entire epoch. Power was computed in dB and the 
sum averaged from 40-80 kHz. Significance was assessed with an unpaired t-test. To 
address the association between receptive auditory processing and expressive 
communicative functioning, dependent measures from ultrasonic vocalization paradigms 
were correlated with AEP indices within each mouse. Pearson R
2
 correlations were 
calculated for AEP and USV measures. Correlations were assessed within 
electrophysiological and behavioral measures, assessing the relationship, for example, 
between adult mating vocalizations and N1 latency.  
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4.4 Results 
The PV-selective NR1 KO mice showed a significant delay in N1 latency 
compare to WT mice (Figure 4.6.1, P<0.001). There was no reduction in N1 amplitude in 
the PV-selective NR1 KO compared to WT mice (Data not shown). The PV-selective 
NR1 KO mice showed significantly reduced sociability compared to WT mice (Figure 
4.6.2, P<0.01). The PV-selective NR1 KO mice showed reduced pre-mating USV power 
compared to WT mice (Figure 4.6.3, 4.6.4. and 4.6.5, P<0.05). There was no difference 
between T-maze results for the two groups of subjects (Figure 4.6.6). There was a 
significant correlation between N1 latency and sociability across all mice (Figure 4.6.7 
R
2
=0.38 and P<0.05) but not between N1 latency and USV or T-maze measures (data not 
shown). There were no significant alterations for amplitude or latency of the P20 ERP 
component in PV-selective NR1 KO mice (P>0.05 for both measures, Data not shown). 
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4.5 Discussion 
The current study demonstrates that the N1 latency, sociability, and pre-mating 
USV changes present in the PV-selective NR1 KO model mimic the phenotypes present 
in ASD. N1 latency delays matched those found in ASD MEG studies that in turn were 
able to discriminate between patients and controls (Gandal, Edgar et al. 2010; Roberts, 
Khan et al. 2010). Latency alterations in the PV-selective NR1 KO mice were specific to 
the N1, with no latency changes observed for the P1 component, also similar to findings 
in ASD. Additionally PV-selective NR1 KO mice showed selective behavioral deficits in 
non-mating social interactions and mating vocalizations without working memory 
deficits. Furthermore, there was a correlation between N1 latency and sociability, 
providing possible evidence of N1 latency as a biomarker for sociability. 
 
Integration of Sensory and Social function: The N1 latency delays in the 
current model of ASD could become an important translational biomarker, with evidence 
that circuits that control N1 latency are also utilized in control or initiation of social 
interactions. The relationship between N1 latency and social function present in mice 
with selective deficits in NMDAR-mediated signaling on PV interneurons could also 
provide insight into possible neural circuits involved with social function. Subsequent 
studies will determine whether normalization of N1 latency relates to increased social 
function. If there is evidence for N1 normalization coinciding with normalization of 
social function, N1 could provide a continuous biomarker for examining the severity of 
social deficits. However, if evidence indicate that it is only associated with the degree of 
initial impairment, then it may be still useful as an early diagnostic guide for disease 
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classification and initial treatment course in pre-language toddlers. This is useful because 
early consistent intervention may result in better outcomes and reduced disability 
(Dawson 2008). 
 
Implications for Cognitive function: The current study does not provide direct 
evidence that NMDAR signaling on PV interneurons impact cognitive function. While 
there is a qualitative reduction in T-maze performance for the PV-selective KO mice, the 
variance in these subjects results in statistically similar performance. This may suggest 
that the current study lacked sufficient power to detect mild cognitive deficits in PV-
selective NR1 KO mice. However, the sample size was sufficient to detect social deficits, 
suggesting a relatively selective deficit in this domain. Therefore, this work advances our 
understanding of autisms, and suggests that it may be a set of diseases with disrupted 
glutamate innervation of interneurons. Further, we propose that N1 latency has the 
potential to be an index of social function that may be used in development of novel 
therapeutics. 
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4.6 FIGURE LEGENDS 
Figure 4.6.1- N1 Latency 
 
Effect of PV-selective NR1 knockout on N1 latency.  PV-selective NR1 KO mice 
exhibit significantly delayed N1 latencies compared to WT mice.  N1 latency delay is a 
robust marker of autism and combined with sociability specific deficits, indicates these 
mice have a constellation of autism like phenotypes.  Figures show the mean + SEM.  
(*** P<0.001). 
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Figure 4.6.2- Sociability 
 
Effect of PV-selective NR1 knockout on Sociability.  In a two cylinder social task, PV-
selective NR1 KO mice showed significantly reduced preference for the social cylinder 
compared to WT mice.  This indicates a reduction in sociability for the PV-selective NR1 
KO mice compared to WT.  Figures show the mean + SEM.  (** P<0.01). 
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Figure 4.6.3- Raw Premating Vocalization Data 
 
Example raw data for premating vocalizations.  Example demonstrates spectrograms 
of calls for analysis of call frequency range. 
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Figure 4.6.4- USV Vocalization Power 
 
USV vocalization spectrum.  PV-selective NR1 KO mice showed significantly reduced 
mating USVs in the presence of female mice as compared to WT mice. 
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Figure 4.6.5- Mating USV Power 
 
 
Effect of PV-selective NR1 knockout on USV pre-mating call power.  PV-selective 
NR1 KO mice showed significantly reduced pre-mating USVs in the presence of female 
mice as compared to WT mice.  This indicates that in both non-mating (Figure 4.6.2), and 
mating scenarios, PV-selective NR1 KO mice show reduced social interaction 
phenotypes compared to WT mice.  Figures show the mean + SEM.  (* P<0.05). 
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Figure 4.6.6- T-maze 
 
 
Effect of PV-selective NR1 knockout on T-maze task performance.  WT and PV-
selective NR1 KO mice showed similar T-maze performance, indicating a lack of 
cognitive deficits.  This indicates that alterations in NMDA receptor expression on PV 
interneurons do not lead to reductions in working memory.  Figures show the mean + 
SEM. 
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Figure 4.6.7- N1 latency to Social Preference Correlation 
 
Correlation for between N1 latency and Sociability among all mice.  The combined 
PV-selective NR1 KO and WT groups show a correlation between N1 latency and social 
time (R
2
=0.38, P<0.05).  This supports the hypothesis that N1 latency is a possible 
marker for sociability, and the severity of autism symptoms.  Furthermore, combined 
with selective socially deficits, and autism specific electrophysiological changes, this 
supports the PV interneuron NMDAR knockout mouse as a model for autism. 
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Chapter 5: Summary and Conclusions 
5.1 Summary 
This thesis explores several pre-clinical glutamate disruption mouse models that 
mimic the electrophysiological changes, negative and cognitive deficits present in autism 
and schizophrenia. Using glutamate disruption as a model we demonstrate how EEG can 
provide an independent measure to examine different aspects of circuit function. 
Furthermore, a main advantage of EEG techniques is that various signal processing 
methods allowing for much richer examination of new and existing EEG data frequency 
content such as the theta and gamma frequencies, which are thought to reflect separate 
brain processes. There are also works showing that different EEG measures  have 
associations to disease symptoms(Olichney, Iragui et al. 1998; Gruzelier, Richardson et 
al. 1999; Light, Hsu et al. 2006; Evans, Gray et al. 2007).  
The benefit of investigating glutamate disruption models with improved analyses 
is a more thorough understanding of the circuits disrupted in both diseases. For example, 
analyzing the data’s inter-trial coherence gives a measure of circuit firing consistency, 
and gives a measure of the firing precision in the circuit. Inter-trial coherence has been 
related to working memory in subjects, providing evidence that loss of circuit timing 
consistency has functional outcomes (Light, Hsu et al. 2006). Additionally, examining 
evoked power provides data on the ability of the circuit to mount a response in different 
frequency bands, and in tandem with analyzing the baseline data can be combined to 
understand the signal to noise ratio of the circuit (Gandal, Edgar et al. 2011). 
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In this thesis, high levels of glutamate disruption via high dose NMDA antagonist 
administration shows evidence of mimicking schizophrenia like electrophysiological 
symptoms in gamma activity, and ERP components. Additionally, factor analysis was 
performed to understand the relationship between different circuit measures. The 
outcome was that the circuits that drive gamma band signal to noise were found to be 
disrupted independently of coherence, total power, and ERP amplitude circuits. Low 
level glutamate disruption using MK801 was used as a model for autism. This study 
revealed N1 latency prolongation, reduced gamma ITC, and evoked power in line with 
autism electrophysiological endophenotypes. Previous studies using  low dose NMDA 
antagonist administration that have shown a plethora of negative and cognitive 
symptoms, including social impairments and working memory disruption (van der Staay, 
Rutten et al. ; Zou, Zhang et al. 2008). PV NMDA receptor knockdown mice were also 
explored, with observations showing lengthening of N1 latency in line with autism. 
Behavioral tests were performed in tandem, revealing the mice had selective sociability 
and pre-mating vocalization deficits, in the absence of statistically significant cognitive 
deficits. This suggests that the NMDA receptors on PV interneurons are selectively 
involved in EEG circuits involved in latency control and social function. As a whole, 
NMDAR disruption of PV interneurons appears to recreate the electrophysiological and 
behavioral phenotypes of negative symptoms. In addition, the electrophysiological and 
social interaction deficits appear to be caused by similar PV interneuron-based circuit 
disruptions, and this work provides evidence that in at least some cases the EEG is a 
direct index of function. This work provides evidence that EEG measures could be used 
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as specific measures of functional outcomes, with future work including clinical 
comparisons. 
81 
 
5.2 Future Directions 
Patch studies examining parvalbumin interneuron excitability would be 
productive in showing what aspects of cellular function are changing when NMDA 
receptors are knocked out, to understand what the change is in the basic unit of circuit 
that causes system wide changes. Correlating the markers with further behavioral data, 
possibly comparing the dose response curves of EEG changes post NMDA antagonist 
disruption with similar curves in behavioral studies could help validate the markers as 
indices of function. Testing existing ineffective treatments that do not ameliorate 
symptoms as negative controls will be necessary to establish the markers validity as 
predictive markers. Further clinical study of the markers to understand their relationship 
to functional outcomes and limits as indices of symptoms, is required before they can be 
used as translational biomarkers for therapeutic development.  
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5.3 Conclusions 
NMDAR disruption is a promising model of the negative and cognitive symptoms 
present in autism and schizophrenia based on accumulating evidence that NMDAR 
disruption underlies the negative and cognitive deficits present in autism and 
schizophrenia. Using these models and the techniques being established clinically and 
pre-clinically to examine the EEG endophenotypes, non-invasive, circuit-based, 
translational biomarkers are being developed to combat the diseases. While further 
development is required to fully utilize these measures in advancing clinical 
development, they are possible tools for understanding brain circuit dysfunction and aid 
in therapeutic development. 
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